Email this article Efficacy of metformin in abdominal obesity
- Authors: Mkrtumian AM1, Markova TN2, Kichigin VA3, Podachina SV1, Zhuchkova SM4
-
Affiliations:
- ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
- ГБУЗ Москвы "Городская клиническая больница №52 Департамента здравоохранения Москвы"
- ФГБОУ "Чувашский государственный университет им. И.Н. Ульянова" Минобрнауки РФ
- БУ "Городская клиническая больница №1" Минздрава Чувашии, Чебоксары
- Issue: Vol 86, No 8 (2014)
- Pages: 80-84
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31573
- ID: 31573
Cite item
Full Text
Abstract
AIM. To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO). MATERIALS AND METHODS. The results of using metformin 2000 mg daily for 3 months in 46 patients with АО. The comparison group consisted of 50 people. BW, WC, and blood pressure (BP) were measured; lipid profile parameters and blood insulin concentrations were determined; and Homeostasis Model Assessment (HOMA) estimates were calculated. Metabolic syndrome (MS) and AO were judged by the 2005 International Diabetes Federation (IDF) criteria. RESULTS. The study and comparison groups showed were reductions in BW by 4.2 and 1.7 kg and in WC by 4.2 and 1.1 cm, respectively. Metformin used in the patients with AO contributed to a more significant improvement in the lipid profile than in those who received no medication. A decrease in the HOMA index was observed only in the metformin group. The effects of the drug were more pronounced in MS and insulin resistance. The use of metformin in the patients with AO decreased lower BW and HOMA index and improved lipid metabolism even in the absence of MS. CONCLUSION. The trial has demonstrated that the people with AO may take metformin could be used in to reduce BW and WC and to treat and prevent MS.
Full Text
##article.viewOnOriginalSite##About the authors
A M Mkrtumian
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Email: vagrashot@mail.ru
T N Markova
ГБУЗ Москвы "Городская клиническая больница №52 Департамента здравоохранения Москвы"
V A Kichigin
ФГБОУ "Чувашский государственный университет им. И.Н. Ульянова" Минобрнауки РФ
S V Podachina
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
S M Zhuchkova
БУ "Городская клиническая больница №1" Минздрава Чувашии, Чебоксары
References
- International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/IDF_ Metasyndrome_definition.pdf. Accessed August 24, 2005.
- Ожирение: этиология, патогенез, клинические аспекты. Под ред. И.И. Дедова, Г.А. Мельниченко. М: МИА 2004.
- Diabetes Prevention Program Research Group. Long-term safety, tolerability,and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731-772.
- Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. (второй пересмотр). М 2009; 32.
- Берштейн Л.М. Метформин и онкологическая заболеваемость. Сахарный диабет 2010; 3: 66-71.
- Смирнова О.М. Место метформина в современном лечении и профилактике сахарного диабета 2-го типа. Сахарный диабет 2010; 3: 83-90.
- Дедов И.И., Бутрова С.А., Мищенко Б.П., Дзгоева Ф.Х. Применение метформина (Сиофора) у больных с абдоминальным типом ожирения. Пробл эндокринол 2000; 5: 25-29.
- Gokcel A., Gumurdulu Y., Karakose H. et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4 (1): 49-55.
- Shin M.J., Hyun Y.J., Kim O.Y. et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 2006; 30 (10): 1529-1534.
- Levri K.M., Slaymaker E., Last A. et al. Metformin as treatment for overweight and obese adults - a systematic review. Ann Fam Med 2005; 3: 457-461.
- Seifarth C., Schehler B., Schneider H.J. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121 (1): 27-31.
- Desilets A.R., Dhakal-Karki S., Dunican K.C. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42 (6): 817-826.
- Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
- Salpeter S.R., Buckley N.S., Kahn J.A., Salpeter E.E. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121 (2): 149-157.
- Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistanceand beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
- Ascaso J.F., Pardo S., Real J.T. et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325.
- Диагностика и лечение метаболического синдрома. Национальные рекомендации. Кардиоваск тер и проф 2007; 6 (6) Приложение 2: 22 с.
- Cefalu W.T., Cannon C.P. Atlas cardiometabolic risk. New York 2007; 172.
- Mannucci E., Ognibene A., Cremasco F. et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabeticsubjects. Diabetes Care 2001; 24 (3): 489-494.
